Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7259   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2017-004139-35
    Sponsor's Protocol Code Number:MNK14112096
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2018-03-19
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-004139-35
    A.3Full title of the trial
    A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscular Dystrophy
    Estudio multicéntrico, aleatorizado, de grupos paralelos, doble ciego, de dosis múltiples y controlado con placebo para evaluar la eficacia y la seguridad de MNK-1411 en varones de 4 a 8 años de edad con distrofia muscular de Duchenne.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical Trial in Male Subjects with Muscular Disease
    Ensayo clinico en varones con enfermad muscular
    A.4.1Sponsor's protocol code numberMNK14112096
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMallinckrodt ARD Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMallinckrodt ARD Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMallinckrodt ARD Inc.
    B.5.2Functional name of contact pointClinical Trial Lead
    B.5.3 Address:
    B.5.3.1Street Address1425 Route 206
    B.5.3.2Town/ cityBedminster
    B.5.3.3Post codeNJ 07921
    B.5.3.4CountryUnited States
    B.5.4Telephone number34900834223
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCosyntropin acetate
    D.3.2Product code MNK-1411
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 22633-88-1
    D.3.9.3Other descriptive nameCosyntropin acetate
    D.3.9.4EV Substance CodeSUB35804
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSuspension for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Duchenne Muscular Distrophy
    Distrofia muscular de Duchenne
    E.1.1.1Medical condition in easily understood language
    Muscular Disease
    Enfermedad muscular
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10013801
    E.1.2Term Duchenne muscular dystrophy
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the effect of MNK-1411 on motor function in subjects with DMD.
    Determinar el efecto de MNK-1411 sobre la función motora en pacientes con DMD.
    E.2.2Secondary objectives of the trial
    1-To assess the effect of MNK-1411 on motor skills and strength.
    2-To determine the safety and tolerability of MNK-1411 in subjects with DMD.
    1- Evaluar el efecto de MNK-1411 sobre las capacidades motoras y la fuerza.
    2- Determinar la seguridad y tolerabilidad de MNK-1411 en pacientes con DMD
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects must meet all of the following criteria for inclusion in the study at the Screening Visit and at the Baseline Visit (except as noted):
    1. Each subject’s parent or legal guardian must be adequately informed and understand the nature and risks of the study and must be able to provide a signature and date on the ICF. In addition, each subject who is capable of understanding it must sign an assent form. The
    consent and assent (where applicable) for this study must be signed before any protocol required procedures are performed.
    2. Subjects must be male and between 4 and 8 years of age (inclusive) at the Screening Visit.
    3. Subjects must have a documented diagnosis of DMD confirmed by complete dystrophin deficiency (by immunofluorescence and/or immunoblot), or identifiable mutation in the DMD gene where reading frame can be predicated as “out of frame”, or complete
    dystrophin gene sequencing consistent with DMD; AND in the opinion of the Investigator, a typical clinical profile consistent with DMD.
    4. Subjects taking approved treatments for DMD (by a Health Authority) that target dystrophin gene mutations (eg, eteplirsen or ataluren) may be enrolled in the study if they have been on a stable dose for 30 days prior to the first dose of study drug, and plan to
    remain on that dose throughout the study
    5. Subjects should have serum potassium within the reference range at screening. Subjects who have potassium levels below the lower limit of normal may be given potassium supplements and then retested within the 28 day screening period.
    6. Subjects and/or subjects’ parent or legal guardian must be able to communicate effectively with study personnel.
    7. Subjects and subjects’ parent or legal guardian must be able and willing to follow all protocol requirements and study restrictions.
    8. Subjects and subjects’ parent or legal guardian must be able and willing to return for all study visits.
    Para poder participar en el estudio, los pacientes deben cumplir todos los criterios siguientes en la visita de selección y en la visita basal (excepto cuando se indique lo contrario):
    1. El progenitor o tutor de cada paciente debe estar correctamente informado, debe comprender la naturaleza y los riesgos del estudio y debe ser capaz de firmar y fechar el DCI. Además, los pacientes capaces de entenderlo deberán firmar un documento de asentimiento. El consentimiento y el asentimiento (según proceda) de este estudio deberán firmarse antes de efectuar cualquiera de los procedimientos requeridos por el protocolo.
    2. Los pacientes deben ser varones y tener entre 4 y 8 años de edad (ambos inclusive) en la visita de selección.
    3. Los pacientes deben tener un diagnóstico documentado de DMD, confirmado por una carencia completa de distrofina (por inmunofluorescencia o inmunotransferencia), una mutación identificable del gen de la DMD que pueda pronosticarse que está «fuera del marco de lectura» o una secuenciación completa del gen de la distrofina que sea compatible con la DMD; Y TAMBIÉN, en opinión del investigador, un perfil clínico típico compatible con la DMD.
    4. Los pacientes que estén tomando tratamientos aprobados para la DMD (por una autoridad sanitaria) que actúen sobre las mutaciones del gen de la distrofina (por ejemplo, eteplirsén o atalurén) podrán participar en el estudio si la dosis ha permanecido estable durante los 30 días previos a la primera dosis de fármaco del estudio y tienen previsto seguir con esa misma dosis durante todo el estudio.
    5. Los pacientes deberán tener el potasio sérico dentro del intervalo normal en la selección. Los pacientes con concentraciones de potasio por debajo del límite inferior de la normalidad podrán recibir suplementos de potasio y volver a analizarse dentro del periodo de selección de 28 días.
    6. El paciente o su progenitor o tutor deberán ser capaces de comunicarse eficazmente con el personal del estudio.
    7. El paciente y su progenitor o tutor deberán ser capaces de seguir todos los requisitos del protocolo y las restricciones del estudio, y estar dispuestos a hacerlo.
    8. El paciente y su progenitor o tutor deberán ser capaces de acudir a todas las visitas del estudio y estar dispuestos a hacerlo.
    E.4Principal exclusion criteria
    Subjects are ineligible for study participation if they meet any of the following criteria at the Screening Visit and at the Baseline Visit (except as note):
    1. Subject is from a vulnerable population (excluding pediatric populations), as defined by the US CFR Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full-time, etc) or family members of the research staff conducting the study, or of the sponsor, or of the clinical research organization, or of the IRB/IEC.
    2. Subject has had previous systemic treatment with corticosteroids. Transient previous use of corticosteroids will be evaluated on a case-by-case basis by the sponsor or designee. Inhaled corticosteroids will be permitted if given at a stable dose for the 3 months prior to the first dose of study drug and the subject will remain on that dose throughout the study. The use of topical or intra-articular corticosteroids is permitted during the study.
    3. Subject has been treated with immunosuppressants, or mineralocorticoids (including, but not limited to, spironolactone, eplerone, and carrenone) in the 3 months prior to the Screening Visit.
    4. Subject has taken any investigation medication within 30 days or 5 half lifes (whichever is longer) prior to the first dose of study drug.
    5. Subject is unwilling to receive, or is intolerant of, SC injections.
    6. Subject has symptomatic cardiomyopathy in the opinion of the investigator.
    7. Subject is unable to complete the 10 meter Walk/Run test at the Screening and/or Baseline Visit.
    8. Subject has a history of any drug allergy, hypersensitivity, or intolerance to cosyntropin, H.P. Acthar® Gel or other ACTH products.
    9. Subject has a history or evidence of active infection or febrile illness within 7 days prior to the Screening Visit or subject has a clinically significant infection requiring administration of intravenous antibiotics or hospitalization in the 4 weeks prior to the Screening Visit or between the Screening Visit and the first dose of study drug.
    10. Subject has any known contraindication(s) to the class of ACTH products including, but not limited to:
    Acute psychoses.
    Any primary adrenocortical insufficiency or adrenal cortical hyperfunction.
    Cushing’s Syndrome.
    Any current congestive heart failure (defined as New York Heart Association Functional Class III to IV).
    Peptic ulcer (within 24 weeks prior to the Screening Visit).
    Recent major surgery (within 24 weeks prior to the Screening Visit).
    11. Subject has Type 1 or Type 2 diabetes mellitus.
    12. Subject has a history of chronic active hepatitis including acute or chronic hepatitis B, or acute or chronic hepatitis C.
    13. Subject has a history of tuberculosis (TB) infection, any signs/symptoms of TB, or any close contact with an individual with an active TB infection.
    14. Subject has known immune compromised status (not related to disease/condition under study), including but not limited to, individuals who have undergone organ transplantation or who are known to be positive for the human immunodeficiency virus.
    15. Subject has any solid tumor or hematologic malignancy currently diagnosed or undergoing therapy, or has received therapy for any solid tumor or hematological malignancy in the 5 years prior to the Screening Visit; with the exception of treated and cured basal cell
    carcinoma or treated and cured squamous cell carcinoma of the skin.
    16. Subject has any of the following laboratory abnormalities at the Screening Visit:
    Hemoglobin ≤ 8.0 g/dL.
    Platelets ≤ 50,000 cells/μL.
    Absolute neutrophil count ≤ 1000 cells/μL.
    Glycosylated hemoglobin (HbA1c) > 6.5%.
    Positive Hepatitis B surface antigen (HBsAg) or Hepatitis B core antibody (HBcAb), or positive Hepatitis C virus antibody (HCV). (If HCV is positive at screening, HCV polymerase chain reaction (PCR) will be automatically analyzed. Subjects with a positive HCV must have HCV PCR < 25 IU/mL at the Screening Visit to be eligible).
    Positive or indeterminate interferon gamma release assay (IGRA) for TB.
    17. Subject has any other clinically significant disease, disorder or laboratory abnormality which, in the opinion of the investigator (by its nature or by being inadequately controlled), might put the patient at risk due to participation in the study, or may influence the results of the study or the subject’s ability to complete the study.
    No podrán participar en el estudio los pacientes que cumplan cualquiera de los siguientes criterios de exclusión en la visita de selección y en la visita basal (excepto como se indica):
    1. El paciente pertenece a una población vulnerable (excluidas las poblaciones pediátricas) según la definición del CFR estadounidense, Título 45, Parte 46, Sección 46.111(b), y otros reglamentos locales y nacionales, lo que incluye, entre otros, a empleados (temporales, a tiempo parcial, a tiempo completo, etc.) y familiares del equipo investigador que realiza el estudio, del promotor, de la organización de investigación por contrato o del CEIm.
    2. El paciente ha recibido anteriormente tratamiento sistémico con corticosteroides. El promotor o una persona nombrada por él evaluará caso por caso el uso transitorio previo de corticosteroides. Los corticosteroides inhalados se permitirán si se administran en dosis estables desde 3 meses antes de la primera dosis de fármaco del estudio y el paciente va a mantener esas mismas dosis durante todo el estudio. El uso tópico o intrarticular de corticosteroides está permitido durante el estudio.
    3. El paciente ha recibido tratamiento con inmunodepresores o mineralocorticoides (incluidos, entre otros, espironolactona, eplerona y carrenona) en los 3 meses previos a la visita de selección.
    4. El paciente ha recibido cualquier medicamento experimental en los 30 días o el período correspondiente a 5 semividas (lo que suponga más tiempo) anteriores a la primera dosis de fármaco del estudio
    5. El paciente no desea recibir inyecciones SC o no las tolera.
    6. El paciente tiene una miocardiopatía sintomática en opinión del investigador.
    7. El paciente es incapaz de realizar la prueba de los 10 metros andando o corriendo en la visita de selección y/o la visita basal.
    8. El paciente tiene antecedentes de alergia a cualquier fármaco, de hipersensibilidad o de intolerancia a cosintropina, H.P. Acthar® Gel u otros productos con ACTH.
    9. El paciente tiene antecedentes o signos de infección activa o un cuadro febril en los 7 días previos a la visita de selección o padece una infección clínicamente significativa que requiere antibióticos intravenosos o ingreso hospitalario en las 4 semanas anteriores a la visita de selección o entre la visita de selección y la primera dosis de fármaco del estudio.
    10. El paciente tiene cualquier contraindicación conocida con respecto a la clase de productos de ACTH, como serían, entre otras:
    • Asma
    • Psicosis aguda
    • Cualquier insuficiencia o hiperfunción corticosuprarrenal primaria.
    • Síndrome de Cushing
    • Insuficiencia cardíaca congestiva (definida como de clase III-IV de la New York Heart Association)
    • Úlcera péptica (en las 24 semanas previas a la visita de selección)
    • Intervención de cirugía mayor reciente (en las 24 semanas previas a la visita de selección)
    11. El paciente tiene diabetes mellitus de tipo 1 o 2.
    12. El paciente tiene antecedentes de hepatitis crónica activa, incluidas las hepatitis B y C agudas o crónicas.
    13. El paciente tiene antecedentes de tuberculosis (TB), signos o síntomas de TB, o cualquier tipo de contacto íntimo con una persona que tenga TB activa.
    14.El paciente presenta una inmunodepresión conocida (sin relación con la enfermedad o trastorno que se estudia), como ocurre, entre otras, con las personas sometidas a un trasplante de órgano o que están infectadas por el virus de la inmunodeficiencia humana.
    15. El paciente tiene cualquier tumor sólido o cáncer hematológico actualmente diagnosticado o en tratamiento, o ha recibido tratamiento para cualquier tumor sólido o cáncer hematológico en los 5 años previos a la visita de selección, excepción hecha del carcinoma basocelular tratado y curado y del carcinoma espinocelular de la piel tratado y curado.
    16. El paciente presenta alguna de las anomalías analíticas siguientes en la visita de selección:
    • Hemoglobina ≤ 8,0 g/dl.
    • Plaquetas ≤ 50.000 células/μl.
    • Recuento absoluto de neutrófilos ≤ 1000 células/μl.
    • Hemoglobina glucosilada (HbA1c)  6,5 %.
    • Antígeno de superficie de la hepatitis B (HBsAg) o anticuerpo central de la hepatitis B (HBcAb) positivo, o anticuerpos positivos contra el virus de la hepatitis C (VHC). (Si el VHC es positivo en la selección, se efectuará automáticamente una reacción en cadena de la polimerasa (PCR) para analizar el VHC. Los pacientes con positividad el VHC deben tener una PCR del VHC < 25 UI/ml en la visita de selección para poder participar).
    • Análisis positivo o indeterminado de liberación de interferón gamma (IGRA) para la TB.
    17. El paciente tiene cualquier otra enfermedad, trastorno o anomalía analítica clínicamente importante que, en opinión del investigador (por su naturaleza o por estar mal controlada), podría poner al paciente en situación de riesgo en caso de participar en el estudio, o influir en los resultados del estudio o en la capacidad del paciente para completar la investigación.
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline in 10 meter walk/run time
    Variación del tiempo empleado en andar/correr 10 metros desde el momento basal
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 24
    Semana 24
    E.5.2Secondary end point(s)
    1-Change from baseline in quantitative muscle testing, the 4 Stair Climb, Time to Stand, and the North Star Ambulatory Assessment (NSAA)
    2-Summary of general safety profile, including AEs, vital signs, immunogenicity, and laboratory assessments over the entire study.
    1.- Variacion desde el momento basal en las pruebas musculares cuantitativas, tiempo para subir 4 escaleras normalizadas, tiempo para ponerse de pie desde la posición supina y Evaluación ambulatoria North Star (NSAA)

    2.- Resumen del perfil de seguridad general, incluyendo AE, signos vitales, inmunogenicidad y evaluaciones de laboratorio durante todo el estudio.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1-Week 24
    2-Over the entire study
    1- Semana 24

    2.- Durante todo el estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA25
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Follow-up visit:
    -Subjects who complete the study and do not enter the open label extension will have their Follow-up Visit at approximately Week 28.
    -Subjects who complete the open label extension will have their Follow-up Visit at approximately Week 52.
    Última visita de seguimiento:
    - Los sujetos que completen el estudio y no entren en la fase de extension abierta tendrán su Visita de seguimiento aproximadamente en la semana 28.
    -Los sujetos que completen la fase extensión abierta tendrán su Visita de seguimiento aproximadamente en la semana 52.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 132
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F. of subjects for this age range: 132
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female No
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state8
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 100
    F.4.2.2In the whole clinical trial 132
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-06-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-05-30
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2019-12-19
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands